文献速递白血病

前泊那替尼时代与后泊那替尼时代T315I突变慢性髓性白血病患者的特征与结局

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
PubMed 文献 · Am J Hematol · 2023-07-23

该研究回顾了2004年3月15日至2022年7月26日期间检测到T315I突变的107例慢性期、加速期或急变期慢性髓性白血病患者,中位随访75个月时中位总生存期为49个月、5年总生存率为44%;突变检测时处慢性期者5年总生存率为70%,接受泊那替尼和/或阿西米尼治疗的慢性期患者5年总生存率为77%,与其他治疗组的50%相比差异未达统计学显著(p=0.14)。

要点

  • T315I突变检测时处慢性期者中位总生存期132个月,5年总生存率70%。
  • 慢性期患者接受泊那替尼和/或阿西米尼5年总生存率77%,其他治疗50%(p=0.14)。
  • 突变检测时处加速期和急变期者中位总生存期分别为31个月和6个月。

核心结论

  • T315I突变检测时处慢性期的慢性髓性白血病患者可能病程相对惰性,长期总生存率达70%。
  • 第三代酪氨酸激酶抑制剂治疗似乎改善慢性期患者的生存。

研究设计与样本

  • 回顾性分析2004年3月15日至2022年7月26日期间检测到T315I突变的慢性髓性白血病慢性期或加速期患者。
  • 共纳入107例患者,突变检测时54例(51%)处慢性期、14例(13%)处加速期、39例(36%)处急变期。
  • 102例患者在检测到T315I突变后接受了后续治疗。
  • 总生存期定义为从突变检测时至死亡或末次随访日期。

主要发现

  • 中位随访75个月(95%CI,41-110),中位总生存期为49个月(95%CI,26-73),5年总生存率为44%。
  • 突变检测时处慢性期、加速期和急变期患者的中位总生存期分别为132、31和6个月,5年总生存率分别为70%、37%和10%(p<0.001)。
  • 慢性期患者接受泊那替尼和/或阿西米尼治疗的5年总生存率为77%,接受其他治疗(化疗、第二代酪氨酸激酶抑制剂、高三尖杉酯碱和研究性药物)者为50%(p=0.14)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with chronic myeloid leukemia (CML) and T315I mutation generally have a poor prognosis. Their outcome in the post-ponatinib era remains unclear. We reviewed patients with CML in chronic (CP) or accelerated phase (AP) who developed a T315I mutation between March 15, 2004, and July 26, 2022. Patients were divided into CP, AP, or blastic phase (BP) at the time of mutation detection. Overall survival (OS) was defined from the time of mutation detection to the date of death or last follow-up. We identified a total of 107 patients: 54 (51%) in CP, 14 (13%) in AP, and 39 (36%) in BP. One hundred and two patients received subsequent therapy after the T315I mutation was detected. At a median follow-up of 75 months (95% CI, 41-110), the median OS was 49 months (95% CI, 26-73) and the 5-year OS rate was 44%. Patients who were in CML-CP at the time of mutation detection had better survival compared with those in AP or BP, with a median OS of 132, 31, and 6 months, and 5-year OS rates of 70%, 37%, and 10%, respectively (p < .001). Patients with CML-CP treated with ponatinib and/or asciminib had a 5-year OS of 77% compared with 50% in those who received other treatments (chemotherapy, second-generation tyrosine kinase inhibitors, homoharringtonine, and investigational drugs) (p = .14). In summary, patients with CML-CP at the time of T315I mutation detection may have a relatively indolent disease course with a long-term OS of 70%. Treatment with third-generation tyrosine kinase inhibitors seemed to improve survival in patients with CML-CP.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Haddad FG, Sasaki K, Bidikian A, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol. 2023. PMID: 37485584. doi:10.1002/ajh.27037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。